290
Views
20
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Downregulated expression of miR-155, miR-17, and miR-181b, and upregulated expression of activation-induced cytidine deaminase and interferon-α in PBMCs from patients with SLE

, , , , , , & show all
Pages 865-870 | Received 03 Dec 2014, Accepted 13 Mar 2015, Published online: 29 Jun 2015
 

Abstract

Objective. Recent studies on systemic lupus erythematosus (SLE) revealed that microRNAs (miRNAs or miRs) were involved in its pathogenesis. However, only a limited number of miRNAs have been examined.

Methods. We performed quantitative real-time reverse transcription-polymerase chain reaction analyses of peripheral blood mononuclear cells (PBMCs) obtained from 31 untreated SLE patients and 31 healthy subjects to examine the expression levels of miR-155, miR-17, and miR-181b, as well as those of activation-induced cytidine deaminase (AID) and interferon-α (IFN-α) messenger RNAs (mRNAs). We examined the relationship between miR-181b, AID, and IFN-α with a luciferase reporter assay.

Results. The expression levels of miR-155, miR-17, and miR-181b were significantly lower in SLE patients than those in healthy controls, whereas those of AID and IFN-α mRNAs were significantly higher in SLE patients than those in healthy controls. The expression levels of miR-155, miR-17, and miR-181b inversely correlated with those of AID and IFN-α mRNAs in SLE patients. The results of the luciferase reporter assay revealed that miR-181b negatively regulated AID and IFN-α.

Conclusions. The results of the present study demonstrated for the first time that there is a differential expression and inverse correlation between the levels the miR-155, miR-17, and miR-181b and target molecules, AID and IFN-α mRNAs, in PBMCs of untreated SLE patients. These alterations may contribute to the pathogenesis of SLE.

Acknowledgments

We wish to express our appreciation to Ms. Keiko Iwamoto for her technical assistance.

Conflict of interest

None.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.